Pasithea Therapeutics (KTTA) Liabilities and Shareholders Equity (2020 - 2026)

Pasithea Therapeutics' Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $56.4 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 284.44% year-over-year to $56.4 million; the TTM figure through Mar 2026 stood at $147.2 million (up 119.67% YoY), while the FY2025 annual figure was $60.2 million, up 274.98% from the prior year.
• Liabilities and Shareholders Equity came in at $56.4 million for Q1 2026 at Pasithea Therapeutics, down from $60.2 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $60.2 million in Q4 2025 to a low of $13.6 million in Q3 2025.
• A 5-year average of $33.7 million and a median of $30.7 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity tumbled 53.7% in 2024 and jumped 284.44% in 2026, its largest moves.
• Pasithea Therapeutics' Liabilities and Shareholders Equity stood at $45.2 million in 2022, then tumbled by 42.19% to $26.1 million in 2023, then tumbled by 38.49% to $16.1 million in 2024, then surged by 274.98% to $60.2 million in 2025, then declined by 6.45% to $56.4 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $56.4 million, $60.2 million, and $13.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison